(BioNTech) BioNTech expects to hit its 2022 vaccine revenue guidance of between 13 billion euros and 17 billion euros.
The affirmed guidance happens after BioNTech reported total revenues of 6.375 billion euros in the first quarter of 2022, increasing from 2.048 billion euros in the prior year.
BioNTech reported a net profit of 3.699 billion euros in the quarter, or 14.24 euros per share, compared to earnings of 1.128 billion euros or 4.39 per share in the prior year.
BioNTech further kept its March plans for a special dividend of 2.00 euros and stock repurchase of up to $1.5 billion in the next two years. The company said that the first tranche of stock buybacks started on May 2.
BNTX: NASDAQ is up +1.70% on premarket
